On Friday, Stifel reaffirmed its Buy rating and $84.00 stock price target for Apellis Pharmaceuticals (NASDAQ:APLS), despite the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issuing a second negative opinion on the company's drug, Syfovre, for the treatment of geographic atrophy (GA) in the EU. The analyst noted that while the EU's decision was disappointing, especially considering Syfovre's strong performance and demand in the U.S. market, it was not entirely unexpected.
According to the analyst, European regulators are not wavering from their requirement for prospective functional data. Apellis has decided not to conduct additional Phase 3 trials to establish functional benefits in the EU but will continue to focus on expanding its market presence in other regions. Despite the EU setback, the firm's valuation of Apellis remains unchanged as EU sales had already been excluded from their forecasts.
The analyst also indicated that minor adjustments have been made to Syfovre's sales estimates to account for potential headwinds, such as seasonal fluctuations or increased competition, but these do not affect the price target. The company's strategy is to continue promoting Syfovre in the U.S., where there is a significant untapped market of approximately 1.5 million GA patients.
Apellis Pharmaceuticals is also expected to concentrate on advancing Empaveli for the treatment of C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN), as per the analyst's comments. These efforts are part of the company's broader initiative to strengthen its position in various therapeutic areas.
In other recent news, Apellis Pharmaceuticals has seen significant developments. The company reported strong Q2 2024 growth, with its drugs SYFOVRE and EMPAVELI generating considerable revenues. SYFOVRE achieved over $0.5 billion in sales since its launch and $155 million in net product revenue in Q2 2024 alone. EMPAVELI also contributed significantly with $24.5 million in sales.
Apellis received a final negative opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding pegcetacoplan's potential European regulatory approval, leading to Mizuho Securities reducing its price target for Apellis to $39 while maintaining a Neutral rating. This development has led to the exclusion of projected European Union revenue from Mizuho's financial model for Apellis.
However, there is optimism around the company's drug pegcetacoplan, marketed as Empaveli, following positive results from the Phase 3 VALIANT study. This trial demonstrated a significant 68% reduction in proteinuria, a marker of kidney damage, in patients with two rare kidney diseases.
Analyst firms such as BofA Securities, Baird, and Jefferies have responded to these developments with varied price targets and ratings. BofA Securities revised its price target for Apellis, reducing it to $61.00 but maintaining a Buy rating.
Baird maintained its Outperform rating and increased the stock's price target to $96, while Jefferies also maintained a Buy rating and increased the price target to $82.00. These developments underline the evolving landscape for Apellis Pharmaceuticals.
InvestingPro Insights
Apellis Pharmaceuticals (NASDAQ:APLS) appears to be navigating through a challenging phase, as reflected in the recent negative opinion from the European Medicines Agency. However, according to InvestingPro Tips, analysts are expecting sales growth in the current year, which aligns with Stifel's outlook on the company's performance in the U.S. market. This anticipated sales growth could be a pivotal factor for investors considering the company's prospects.
InvestingPro Data further highlights that Apellis is operating with a moderate level of debt and has liquid assets that exceed its short-term obligations, indicating a degree of financial stability. Yet, the company is trading near its 52-week low with a high Price/Book multiple of 15.23, which suggests that the stock might be valued richly in terms of its net assets.
Despite the optimism for U.S. sales, analysts have revised their earnings downwards for the upcoming period, and they do not anticipate the company will be profitable this year. This is an important consideration for investors, as it reflects the challenges Apellis faces in achieving profitability amidst its expansion efforts.
For readers interested in a deeper analysis, there are additional InvestingPro Tips available for Apellis Pharmaceuticals, which can be accessed at https://www.investing.com/pro/APLS. These tips can provide more nuanced insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.